These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 33860199)

  • 1. Peripherally Selective CB1 Receptor Antagonist Improves Symptoms of Metabolic Syndrome in Mice.
    Khan N; Laudermilk L; Ware J; Rosa T; Mathews K; Gay E; Amato G; Maitra R
    ACS Pharmacol Transl Sci; 2021 Apr; 4(2):757-764. PubMed ID: 33860199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The hepatic cannabinoid 1 receptor as a modulator of hepatic energy state and food intake.
    Cooper ME; Regnell SE
    Br J Clin Pharmacol; 2014 Jan; 77(1):21-30. PubMed ID: 23452341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity.
    Tam J; Godlewski G; Earley BJ; Zhou L; Jourdan T; Szanda G; Cinar R; Kunos G
    Am J Physiol Endocrinol Metab; 2014 Feb; 306(4):E457-68. PubMed ID: 24381003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel peripheral cannabinoid 1 receptor antagonist, AJ5012, improves metabolic outcomes and suppresses adipose tissue inflammation in obese mice.
    Han JH; Shin H; Park JY; Rho JG; Son DH; Kim KW; Seong JK; Yoon SH; Kim W
    FASEB J; 2019 Mar; 33(3):4314-4326. PubMed ID: 30566396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing and characterizing 4-methyl substituted pyrazol-3-carboxamides leading to the peripheral cannabinoid 1 receptor inverse agonist TM38837.
    Högberg T; Receveur JM; Murray A; Linget JM; Nørregaard PK; Little PB; Cooper M
    Bioorg Med Chem Lett; 2024 Jan; 98():129572. PubMed ID: 38043690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic targeting of the centrally active cannabinoid 1 receptor (CB
    Hirsch S; Hinden L; Naim MB; Baraghithy S; Permyakova A; Azar S; Nasser T; Portnoy E; Agbaria M; Nemirovski A; Golomb G; Tam J
    J Control Release; 2023 Jan; 353():254-269. PubMed ID: 36442615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Peripherally Restricted Cannabinoid 1 Receptor Selective Antagonist TXX-522 with Prominent Weight-Loss Efficacy in Diet Induced Obese Mice.
    Chen W; Shui F; Liu C; Zhou X; Li W; Zheng Z; Fu W; Wang L
    Front Pharmacol; 2017; 8():707. PubMed ID: 29051736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripherally selective diphenyl purine antagonist of the CB1 receptor.
    Fulp A; Bortoff K; Zhang Y; Snyder R; Fennell T; Marusich JA; Wiley JL; Seltzman H; Maitra R
    J Med Chem; 2013 Oct; 56(20):8066-72. PubMed ID: 24041123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control.
    Son MH; Kim HD; Chae YN; Kim MK; Shin CY; Ahn GJ; Choi SH; Yang EK; Park KJ; Chae HW; Moon HS; Kim SH; Shin YG; Yoon SH
    Int J Obes (Lond); 2010 Mar; 34(3):547-56. PubMed ID: 20029379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoacylglycerol lipase deficiency affects diet-induced obesity, fat absorption, and feeding behavior in CB
    Yoshida K; Kita Y; Tokuoka SM; Hamano F; Yamazaki M; Sakimura K; Kano M; Shimizu T
    FASEB J; 2019 Feb; 33(2):2484-2497. PubMed ID: 30265576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-[[5-(trifluoromethyl)pyridin-2-yl]oxy]propanamide (MK-0364), in rodents.
    Fong TM; Guan XM; Marsh DJ; Shen CP; Stribling DS; Rosko KM; Lao J; Yu H; Feng Y; Xiao JC; Van der Ploeg LH; Goulet MT; Hagmann WK; Lin LS; Lanza TJ; Jewell JP; Liu P; Shah SK; Qi H; Tong X; Wang J; Xu SS; Francis B; Strack AM; MacIntyre DE; Shearman LP
    J Pharmacol Exp Ther; 2007 Jun; 321(3):1013-22. PubMed ID: 17327489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats.
    Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M
    Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction.
    Lipina C; Vaanholt LM; Davidova A; Mitchell SE; Storey-Gordon E; Hambly C; Irving AJ; Speakman JR; Hundal HS
    Aging Cell; 2016 Apr; 15(2):325-35. PubMed ID: 26757949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.
    Jacobson LH; Commerford SR; Gerber SP; Chen YA; Dardik B; Chaperon F; Schwartzkopf C; Nguyen-Tran V; Hollenbeck T; McNamara P; He X; Liu H; Seidel HM; Jaton AL; Gromada J; Teixeira S
    Naunyn Schmiedebergs Arch Pharmacol; 2011 Dec; 384(6):565-81. PubMed ID: 21947251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cannabinoid receptor 1 antagonist treatment induces glucagon release and shows an additive therapeutic effect with GLP-1 agonist in diet-induced obese mice.
    Patel KN; Joharapurkar AA; Patel V; Kshirsagar SG; Bahekar R; Srivastava BK; Jain MR
    Can J Physiol Pharmacol; 2014 Dec; 92(12):975-83. PubMed ID: 25361428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid 1 G protein-coupled receptor (periphero-)neutral antagonists: emerging therapeutics for treating obesity-driven metabolic disease and reducing cardiovascular risk.
    Janero DR; Lindsley L; Vemuri VK; Makriyannis A
    Expert Opin Drug Discov; 2011 Oct; 6(10):995-1025. PubMed ID: 22646861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid receptor 1 (CB1) antagonism enhances glucose utilisation and activates brown adipose tissue in diet-induced obese mice.
    Bajzer M; Olivieri M; Haas MK; Pfluger PT; Magrisso IJ; Foster MT; Tschöp MH; Krawczewski-Carhuatanta KA; Cota D; Obici S
    Diabetologia; 2011 Dec; 54(12):3121-31. PubMed ID: 21987346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cannabinoid CB1 receptor antagonist SR141716A (Rimonabant) enhances the metabolic benefits of long-term treatment with oleoylethanolamide in Zucker rats.
    Serrano A; Del Arco I; Javier Pavón F; Macías M; Perez-Valero V; Rodríguez de Fonseca F
    Neuropharmacology; 2008 Jan; 54(1):226-34. PubMed ID: 17467748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Cannabinoid Receptor Type 1 in Insulin Resistance and Its Biological Implications.
    Nagappan A; Shin J; Jung MH
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31035653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The central cannabinoid CB1 receptor is required for diet-induced obesity and rimonabant's antiobesity effects in mice.
    Pang Z; Wu NN; Zhao W; Chain DC; Schaffer E; Zhang X; Yamdagni P; Palejwala VA; Fan C; Favara SG; Dressler HM; Economides KD; Weinstock D; Cavallo JS; Naimi S; Galzin AM; Guillot E; Pruniaux MP; Tocci MJ; Polites HG
    Obesity (Silver Spring); 2011 Oct; 19(10):1923-34. PubMed ID: 21799481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.